<code id='28DC2715AC'></code><style id='28DC2715AC'></style>
    • <acronym id='28DC2715AC'></acronym>
      <center id='28DC2715AC'><center id='28DC2715AC'><tfoot id='28DC2715AC'></tfoot></center><abbr id='28DC2715AC'><dir id='28DC2715AC'><tfoot id='28DC2715AC'></tfoot><noframes id='28DC2715AC'>

    • <optgroup id='28DC2715AC'><strike id='28DC2715AC'><sup id='28DC2715AC'></sup></strike><code id='28DC2715AC'></code></optgroup>
        1. <b id='28DC2715AC'><label id='28DC2715AC'><select id='28DC2715AC'><dt id='28DC2715AC'><span id='28DC2715AC'></span></dt></select></label></b><u id='28DC2715AC'></u>
          <i id='28DC2715AC'><strike id='28DC2715AC'><tt id='28DC2715AC'><pre id='28DC2715AC'></pre></tt></strike></i>

          Home / knowledge / knowledge

          knowledge


          knowledge

          author:hotspot    Page View:9
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In